Home > Annual Financials > AARTI PHARMALABS

AARTI PHARMALABS Financial Statement Analysis
[BOM: 543748|NSE : AARTIPHARM]

The Revenues of AARTI PHARMALABS have increased by 62.11% YoY .
The Earnings Per Share (EPS) of AARTI PHARMALABS has decreased by -99.56 % YoY.
REVENUES
OPERATING MARGIN
PROFIT AFTER TAX
EPS
ROCE

AARTI PHARMALABS Last 5 Annual Financial Results
[BOM: 543748|NSE : AARTIPHARM]

ConsolidatedMar2023
Mar2022
Mar2021
Revenues ₹1,945 Cr₹1,200 Cr₹0.00 Cr
Expenses ₹1,603 Cr₹995 Cr₹0.01 Cr
Operating Profit (Excl OI) ₹342 Cr₹205 Cr₹-0.01 Cr
Other Income ₹2.32 Cr₹4.19 Cr₹0.00 Cr
Interest ₹21 Cr₹12 Cr₹0.00 Cr
Depreciation ₹63 Cr₹42 Cr₹0.00 Cr
Profit Before Tax ₹261 Cr₹155 Cr₹-0.01 Cr
Profit After Tax ₹193 Cr₹122 Cr₹-0.01 Cr
Consolidated Net Profit ₹193 Cr₹122 Cr₹-0.01 Cr
Earnings Per Share (Rs)₹21.35₹4,890.04₹-0.18
PAT Margin (%)9.9510.190.00
ROE(%)13.3518.23-2.02
ROCE(%)16.1119.40-1.87
Total Debt/Equity(x)0.140.250.08

Key Financials

Market Cap : ₹ 5,494.0 Cr
Revenue (TTM) : ₹ 1,852.6 Cr
Net Profit(TTM) : ₹ 216.9 Cr
EPS (TTM) : ₹ 23.9
P/E (TTM) : 25.3

Industry Peers & Returns1W1M1Y
AARTI PHARMALABS 20.2% 31.8% 43.3%
SUN PHARMACEUTICAL INDUSTRIES 2% -0.3% 59.8%
CIPLA 6% 2.8% 50.4%
DR REDDYS LABORATORIES -1.3% -2.8% 31.5%
ZYDUS LIFESCIENCES 2.6% 7.9% 94.3%
DIVIS LABORATORIES 3.7% 5.8% 17.3%
MANKIND PHARMA -6.5% -7.6% 57%
TORRENT PHARMACEUTICALS 3.9% 7.3% 60.6%
LUPIN 3.2% 3.3% 111.9%


AARTI PHARMALABS Revenues
[BOM: 543748|NSE : AARTIPHARM]

Y-o-Y

62.11 %

5 Yr CAGR

0 %

Years Revenues % Change
Mar2023 ₹1,945 Cr
62.11
Mar2022 ₹1,200 Cr
0
Mar2021 ₹0.00 Cr -


AARTI PHARMALABS Operating Profit
[BOM: 543748|NSE : AARTIPHARM]

Y-o-Y

66.64 %

5 Yr CAGR

Positive

Years Operating Profit % Change
Mar2023 ₹342 Cr
66.64
Mar2022 ₹205 Cr
Positive
Mar2021 ₹-0.01 Cr -

Operating Margins
Y-o-Y

2.75 %

5 Yr CAGR

0

Years Operating Margin% % Change
Mar2023 17.58%
2.75
Mar2022 17.11%
0
Mar2021 0% -

AARTI PHARMALABS Profit After Tax
[BOM: 543748|NSE : AARTIPHARM]

Y-o-Y

58.28 %

5 Yr CAGR

Positive

Years Profit After Tax % Change
Mar2023 ₹193 Cr
58.28
Mar2022 ₹122 Cr
Positive
Mar2021 ₹-0.01 Cr -

PAT Margins
Y-o-Y

-2.36 %

5 Yr CAGR

0

Years PAT Margin(%) % Change
Mar2023 9.95 %
-2.36
Mar2022 10.19 %
0
Mar2021 0 % -

AARTI PHARMALABS Earnings Per Share (EPS)
[BOM: 543748|NSE : AARTIPHARM]

Y-o-Y

-99.56 %

5 Yr CAGR

Positive

Years EPS % Change
Mar2023 ₹21
-99.56
Mar2022 ₹4,890
Positive
Mar2021 ₹-0.18 -

AARTI PHARMALABS Return on Capital Employed (ROCE)
[BOM: 543748|NSE : AARTIPHARM]

Y-o-Y

-16.96 %

5 Yr CAGR

Positive

Years ROCE % Change
Mar2023 16.11%
-16.96
Mar2022 19.4%
Positive
Mar2021 -1.87% -

AARTI PHARMALABS Share Price vs Sensex

Current Share Price : ₹606.4
Current MarketCap: ₹ 5,494.0 Cr
Updated EOD on :May 16,2024

Share Price Returns(%) 1 Week 1 Month 1 Year
AARTI PHARMALABS

20.2%

31.8%

43.3%

SENSEX

1.7%

-0.8%

19%

AARTI PHARMALABS related INDICES

BSE Indices1W1M1Y
S&P BSE SMALL CAP 4.2% 2.3% 58.4%
S&P BSE MIDSMALLCAP 4.1% 2.9% 59.6%
S&P BSE HEALTHCARE 3% 0.4% 52.9%
S&P BSE ALLCAP 3% 1% 36%
No NSE index found

You may also like the below Video Courses


FAQ about AARTI PHARMALABS Financials


How the annual revenues of AARTI PHARMALABS have changed ?

The Revenues of AARTI PHARMALABS have increased by 62.11% YoY .

How the Earnings per Share (EPS) of AARTI PHARMALABS have changed?

The Earnings Per Share (EPS) of AARTI PHARMALABS has decreased by -99.56 % YoY .